You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Baxter
Merck
McKesson
McKinsey

Last Updated: February 19, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for BCT197


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug BCT197?

BCT197 is an investigational drug.

There have been 5 clinical trials for BCT197. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2016.

The most common disease conditions in clinical trials are Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive, and Lung Diseases. The leading clinical trial sponsors are Mereo BioPharma, Novartis Pharmaceuticals, and [disabled in preview].

There are seven US patents protecting this investigational drug and one hundred and eleven international patents.

Recent Clinical Trials for BCT197
TitleSponsorPhase
The Effect of Itraconazole on BCT197 Exposure in Healthy Male ParticipantsMereo BioPharmaPhase 1
The Effect of Azithromycin on BCT197 Exposure in Healthy Male VolunteersMereo BioPharmaPhase 1
Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary DiseaseMereo BioPharmaPhase 2

See all BCT197 clinical trials

Clinical Trial Summary for BCT197

Top disease conditions for BCT197
Top clinical trial sponsors for BCT197

See all BCT197 clinical trials

US Patents for BCT197

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BCT197   Start Trial P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD Fulcrum Therapeutics, Inc. (Cambridge, MA)   Start Trial
BCT197   Start Trial 5-membered heterocycle-based p38 kinase inhibitors Novartis AG (Basel, CH)   Start Trial
BCT197   Start Trial 5-membered heterocycle-based p38 kinase inhibitors Novartis AG (Basel, CH)   Start Trial
BCT197   Start Trial 5-membered heterocycle-based P38 kinase inhibitors Novartis AG (Basel, CH)   Start Trial
BCT197   Start Trial 5-membered heterocycle-based p38 kinase inhibitors Novartis AG (Basel, CH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for BCT197

Drugname Country Document Number Estimated Expiration Related US Patent
BCT197 Taiwan 201924676 2037-10-05   Start Trial
BCT197 Uruguay 37918 2037-10-05   Start Trial
BCT197 World Intellectual Property Organization (WIPO) 2019071144 2037-10-05   Start Trial
BCT197 World Intellectual Property Organization (WIPO) 2019071147 2037-10-05   Start Trial
BCT197 Austria 517872 2023-06-26   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Moodys
Colorcon
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.